NAS:ARWR (USA) Also trade in: Germany UK

Arrowhead Pharmaceuticals Inc

$ 27.7 0.18 (0.65%)
Volume: 546,557 Avg Vol (1m): 2,081,716
Market Cap $: 2.62 Bil Enterprise Value $: 2.40 Bil
P/E (TTM): 394.41 P/B: 13.45
Earnings Power Value -645.67
Net Current Asset Value 1.04
Tangible Book 1.87
Projected FCF -0.25
Median P/S Value 96.07
Graham Number 1.72
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked lower than
52.88% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ARWR: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0, Med: 29.08, Max: 10000
Current: 10000
0
10000
Equity-to-Asset 0.60
Equity-to-Asset ranked higher than
88.20% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ARWR: 0.6
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -39.56, Med: 0.76, Max: 0.95
Current: 0.6
-39.56
0.95
Interest Coverage No Debt
Interest Coverage ranked lower than
55.40% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
ARWR: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0, Med: 0, Max: 10000
Current: 10000
0
10000
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 10.97
DISTRESS
GREY
SAFE
Beneish M-Score 178.27
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 13.28%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 6.19
Operating Margin ranked lower than
65.53% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ARWR: 6.19
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -50437.97, Med: -8027.93, Max: 6.19
Current: 6.19
-50437.97
6.19
Net Margin % 10.09
Net Margin ranked lower than
65.78% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ARWR: 10.09
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -51723.42, Med: -10738.97, Max: 10.09
Current: 10.09
-51723.42
10.09
ROE % 6.98
ROE ranked lower than
58.85% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ARWR: 6.98
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -225.02, Med: -72.95, Max: 6.98
Current: 6.98
-225.02
6.98
ROA % 4.66
ROA ranked lower than
62.36% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ARWR: 4.66
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -154.73, Med: -57.97, Max: 4.66
Current: 4.66
-154.73
4.66
ROC (Joel Greenblatt) % 42.01
ROC (Joel Greenblatt) ranked higher than
54.44% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ARWR: 42.01
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -11843.37, Med: -1120.46, Max: 42.01
Current: 42.01
-11843.37
42.01
3-Year Total Revenue Growth Rate 248.30
3-Year Revenue Growth Rate ranked higher than
99.39% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ARWR: 202.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -50.2, Max: 373.6
Current: 202.1
0
373.6
3-Year Total EBITDA Growth Rate 18.20
3-Year EBITDA Growth Rate ranked higher than
76.68% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ARWR: 27.9
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -190.2, Med: 7.3, Max: 74.2
Current: 27.9
-190.2
74.2
3-Year EPS w/o NRI Growth Rate 25.90
3-Year EPS w/o NRI Growth Rate ranked higher than
75.88% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ARWR: 25.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -162.1, Med: 20.6, Max: 75.1
Current: 25.9
-162.1
75.1

» ARWR's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ARWR

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 2834
Compare SZSE:300009 NAS:MYOK NAS:PTCT OSTO:VITR NAS:HALO NYSE:EBS NAS:LGND LSE:GNS NAS:XLRN XSWX:GALE NAS:QURE NAS:IOVA OCSE:ALK B TSE:4974 NAS:PTLA SZSE:002603 NAS:INSM SHSE:600201 NAS:ANAB XKRX:086900
Traded in other countries HDP1.Germany 0HI3.UK
Address 225 South Lake Avenue, Suite 1050, Pasadena, CA, USA, 91101
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Ratios

Current vs industry vs history
PE Ratio (TTM) 394.41
PE Ratio ranked lower than
100.00% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
ARWR: 394.41
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 253.86, Med: 278, Max: 401.85
Current: 394.41
253.86
401.85
PE Ratio without NRI 394.41
PE without NRI ranked lower than
100.00% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
ARWR: 394.41
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 253.86, Med: 278, Max: 401.85
Current: 394.41
253.86
401.85
Price-to-Owner-Earnings 23.01
Price-to-Owner-Earnings ranked lower than
100.00% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
ARWR: 23.01
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 8.7, Med: 15.15, Max: 23.46
Current: 23.01
8.7
23.46
PB Ratio 13.45
PB Ratio ranked lower than
87.42% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ARWR: 13.45
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.94, Med: 4.62, Max: 71.58
Current: 13.45
0.94
71.58
PS Ratio 27.89
PS Ratio ranked lower than
83.75% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ARWR: 27.89
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 4.04, Med: 97.05, Max: 4936
Current: 27.89
4.04
4936
Price-to-Free-Cash-Flow 20.49
Price-to-Free-Cash-Flow ranked lower than
100.00% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
ARWR: 20.49
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 8.24, Med: 13.53, Max: 20.9
Current: 20.49
8.24
20.9
Price-to-Operating-Cash-Flow 20.21
Price-to-Operating-Cash-Flow ranked lower than
100.00% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
ARWR: 20.21
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 8.11, Med: 13.31, Max: 20.6
Current: 20.21
8.11
20.6
EV-to-EBIT 408.84
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ARWR: 408.84
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -48.6, Med: -3.5, Max: 432.7
Current: 408.84
-48.6
432.7
EV-to-EBITDA 225.77
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ARWR: 225.77
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -57.3, Med: -3.55, Max: 239
Current: 225.77
-57.3
239
EV-to-Revenue 25.31
EV-to-Revenue ranked lower than
80.80% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ARWR: 25.31
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -2.5, Med: 98, Max: 5303.9
Current: 25.31
-2.5
5303.9
PEG Ratio 31.14
PEG Ratio ranked lower than
100.00% of 115 companies
in the Biotechnology industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
ARWR: 31.14
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0, Med: 0, Max: 31.14
Current: 31.14
0
31.14
Current Ratio 2.31
Current Ratio ranked higher than
72.35% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ARWR: 2.31
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.01, Med: 3.34, Max: 302.61
Current: 2.31
0.01
302.61
Quick Ratio 2.31
Quick Ratio ranked higher than
73.28% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ARWR: 2.31
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.01, Med: 3.83, Max: 302.61
Current: 2.31
0.01
302.61
Days Sales Outstanding 51.68
Days Sales Outstanding ranked higher than
98.95% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ARWR: 51.68
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 0.79, Med: 22.35, Max: 1982.84
Current: 51.68
0.79
1982.84

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -14.10
3-Year Share Buyback Rate ranked higher than
56.48% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ARWR: -14.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -598.6, Med: -26.3, Max: 0
Current: -14.1
-598.6
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 14.76
Price-to-Tangible-Book ranked lower than
86.24% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ARWR: 14.76
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.04, Med: 6.57, Max: 54.5
Current: 14.76
0.04
54.5
Price-to-Median-PS-Value 0.29
Price-to-Median-PS-Value ranked higher than
50.29% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ARWR: 0.29
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.05, Med: 0.94, Max: 37.87
Current: 0.29
0.05
37.87
Price-to-Graham-Number 16.05
Price-to-Graham-Number ranked lower than
100.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
ARWR: 16.05
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 1.32, Med: 1.53, Max: 16.35
Current: 16.05
1.32
16.35
Earnings Yield (Joel Greenblatt) % 0.24
Earnings Yield (Greenblatt) ranked higher than
62.07% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ARWR: 0.24
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -2594.2, Med: -27.9, Max: 2132.2
Current: 0.24
-2594.2
2132.2

More Statistics

Revenue (TTM) (Mil) $ 94.79
EPS (TTM) $ 0.07
Beta 1.88
Volatility % 73.56
52-Week Range $ 10.41 - 28.46
Shares Outstanding (Mil) 10.53

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y